Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity

The human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%–30% of breast cancer patients. Anti-HER2 therapies have changed the aggressive course of HER2+ breast cancer. In spite of the therapeutic benefits, their cardiotoxicities are major concerns, especially when used concurrently...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadek, Ibrahim, Keaton, Mark, Maihle, Nita J., Tang, Shou-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147109/
https://www.ncbi.nlm.nih.gov/pubmed/30258918
http://dx.doi.org/10.1016/j.gendis.2017.07.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147109/
https://www.ncbi.nlm.nih.gov/pubmed/30258918
http://dx.doi.org/10.1016/j.gendis.2017.07.007

Ejemplares similares